Sugi Predict

Sugi Predict / Compounds / SCHEMBL132407

SCHEMBL132407

SCHEMBL132407

Nc1cccc(C(=O)O)c1C(=O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP5 Q01469 3/20 0.47
▸ FABP7 O15540 2/20 0.47
▸ KMT2A Q03164 3/20 0.45
▸ EPHX2 P34913 1/20 0.43
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ MMP2 P08253 1/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29197926 0.86 FABP5 (0.46) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL30851268 0.86 FABP5 (0.46) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL2355140 0.85 KMT2A (0.46) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL3214759 0.85 FABP5 (0.45) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL3208727 0.85 FABP5 (0.45) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL6031890 0.85 FABP5 (0.45) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL30662743 0.84 FABP5 (0.49) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL1157567 0.84 FABP5 (0.49) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL3209198 0.84 FABP5 (0.44) FABP5FABP7KMT2AEPHX2CA1
SCHEMBL3209510 0.82 FABP5 (0.45) FABP5FABP7KMT2AEPHX2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030244-B1 POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO ARROWHEAD PHARMACEUTICALS INC (US) 2021-04-21 — — EP disclosed
CN-105451743-B For delivering the poly- conjugate of RNAi triggering to tumour cell in the living body 箭头研究公司 2019-11-19 — — CN disclosed
US-9682123-B2 Methods of treating metabolic disease THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-06-20 — — US disclosed
US-20170022497-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo Arrowhead Pharmaceuticals, Inc. 2017-01-26 — — US disclosed
US-9487556-B2 Polyconjugates for delivery of RNAi triggers to tumor cells in vivo Arrowhead Pharmaceuticals, Inc. (US) 2016-11-08 — — US disclosed
EP-3030244-A1 POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO Arrowhead Research Corporation (US) 2016-06-15 — — EP disclosed
CN-105451743-A Polyconjugates for delivery of RNAi triggers to tumor cells in vivo ARROWHEAD RES CORP 2016-03-30 — — CN disclosed
US-20150190466-A1 METHODS OF TREATING METABOLIC DISEASE NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2015-07-09 — — US disclosed
WO-2015021092-A1 POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO ARROWHEAD RESEARCH CORPORATION (US) 2015-02-12 — — WO disclosed
US-20150045573-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo Arrowhead Pharmaceuticals, Inc. 2015-02-12 — — US disclosed
US-20020048763-A1 Human genome-derived single exon nucleic acid probes useful for gene expression analysis AMERSHAM PLC (GB) 2002-04-25 — — US disclosed
US-20020048800-A1 Myosin-like gene expressed in human heart and muscle GE HEALTHCARE LIMITED (GB) 2002-04-25 — — US disclosed
WO-2002026818-A2 HUMAN NEDD-1 AEOMICA, INT. (US) 2002-04-04 — — WO disclosed
WO-2002024718-A1 COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS DIADEXUS, INC. (US) 2002-03-28 — — WO disclosed
US-6331640-B1 TREATMENT OF REPERFUSION INJURIES HOFFMANN-LA ROCHE INC. 2001-12-18 — — US disclosed
WO-2001092524-A2 MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE AEOMICA, INC. (US) 2001-12-06 — — WO disclosed
WO-2000044335-A2 URIDYL PEPTIDE ANTIBIOTIC (UPA) DERIVATIVES, THEIR SYNTHESIS AND USE MICROCIDE PHARMACEUTICALS, INC. (US) 2000-08-03 — — WO disclosed
EP-0824538-A1 SACCHAROPEPTIDES AND DERIVATIVES THEREOF GLYCOMED INCORPORATED (US) 1998-02-25 — — EP disclosed
WO-1996035700-A9 SACCHAROPEPTIDES AND DERIVATIVES THEREOF — 1997-02-13 — — WO disclosed
WO-1996035700-A1 SACCHAROPEPTIDES AND DERIVATIVES THEREOF GLYCOMED INCORPORATED (US) 1996-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022497-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo PAM, PLAUR, M6PR FABP5 3602/4885FABP7 2278/4885KMT2A 734/4885
US-20150045573-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo PAM, PLAUR, M6PR FABP5 3602/4885FABP7 2278/4885KMT2A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.